Introduction: In the scenario of eye problems, cataract is a disease characterized by the opacification of the lens, which leads to a decrease in visual acuity, due to a change in the refractive index. A cataract is the leading cause of blindness worldwide and surgery for its correction is the most performed surgical procedure in the world, with an estimated 19 million surgeries per year. The Femtosecond laser was approved for ophthalmic surgery in 2000, having been recently developed to integrate cataract surgery. Objective: It was to highlight the main clinical and scientific considerations related to the application of the Femtosecond laser in cataract surgery, highlighting its efficacy and safety to the conventional phacoemulsification technique. Methods: The systematic review rules of the PRISMA Platform were followed. The research was carried out from August to October 2022 in Scopus, PubMed, Science Direct, Scielo, and Google Scholar databases, using articles from the last 15 years. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results and Conclusion: A total of 229 articles were found, of which only 55 were part of this systematic review, after an eligibility analysis. Femtosecond laser-assisted cataract surgery appears to be beneficial in some patient groups, ie those with low baseline endothelial cell counts, or those planning to receive multifocal intraocular lenses. However, considering that the advantages of femtosecond laser-assisted cataract surgery may not be clear in all routine cases, it cannot be considered cost-effective. The adoption of the Femtosecond laser in cataract surgery has divided opinions as it results from the adaptation of a technology already used in other areas to a surgical procedure that, at the time, was already successful.

Introduction: In the scenario of eye diseases, diabetic retinopathy and retinal vein occlusion are the two most common ischemic retinopathies in the world. Ischemia is caused by retinal vascular diseases due to decreased blood perfusion and the appearance of areas of retinal non-perfusion. Also, age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in people over 65 years of age in industrialized countries. By 2020, around 200 million people will be affected by AMD worldwide. Objective: the present systematic review study aimed to highlight the main clinical findings of the treatment of ischemic retinopathy and age-related macular degeneration through cell therapy with bone marrow stem cells. Methods: The rules of the Systematic Review-PRISMA Platform were followed. The search was carried out from March 2022 to June 2022 in Scopus, PubMed, Science Direct, Scielo, and Google Scholar databases. The quality of the studies was based on the GRADE instrument. The risk of bias was analyzed according to the Cochrane instrument. Results and Conclusion: It was found 235 articles involving retinitis pigmentosa, macular degeneration, and bone marrow stem cell therapy. A total of 51 were fully evaluated and 28 studies were included and developed in a systematic review in the results field. The symmetrical Funnel Plot does not suggest a risk of bias between the small sample size studies. It was concluded that intravitreal injection of bone marrow-derived stem cells in a patient with retinal vascular occlusion sequelae demonstrated that the procedure is feasible and safe to be performed in humans as there were no signs of infection, inflammation, or development of intraocular tumor formation. Also, neurotrophic effects correlate with vasculature preservation, suggesting that bone marrow-derived stem cells can be used in the treatment of diseases such as retinal degenerations and vasculopathy that currently lack effective treatment. The authors concluded that stem cells can protect retinal cells from degeneration and also suggested that they were able to replace some types of lost retinal neurons.

Introduction: In the context of skin aesthetics, the spotlight is focused on non-invasive cosmetic procedures. Studies have shown that micro-focused transcutaneous ultrasound (MFU). A commercially available device combines MFU with high-resolution ultrasound imaging. Some clinical studies have shown clinical synergy of MFU-high resolution with poly-L-lactic acid and a fractional or diluted CO2 laser with calcium hydroxyapatite. Objective: A systematic review was carried out on the main clinical findings of the use of micro-focused ultrasound and collagen biostimulation, with or without combination with calcium hydroxyapatite and poly-L-lactic acid, in the aesthetics of human skin, to highlight the safety, efficacy, and risk of bias. Methods: The systematic review rules of the PRISMA Platform were followed. The research was carried out from May to June 2022 in Scopus, PubMed, Science Direct, Scielo, and Google Scholar databases. Scientific articles from the last 20 years were selected. The quality of the studies was based on the GRADE instrument. The risk of bias was analyzed according to the Cochrane instrument. Results: A total of 112 articles were found, and 12 articles were included in the systematic review. It has been shown that MFU-high resolution enables non-invasive tightening and lifting of sagging skin, and when combined dilute calcium hydroxyapatite, polycaprolactone, and/or poly-L-lactic acid is effective in improving sagging skin. Conclusion: It was concluded that MFU-high resolution targets the facial superficial musculoaponeurotic system, achieving non-invasive tightening and lifting of sagging skin, and when combined with dilute calcium hydroxyapatite, polycaprolactone, and/or poly-acid L-lactic is effective in improving sagging skin and cellulite.

Introduction: Allergic conjunctivitis (AC) is a disease of increasing prevalence, affecting children and adults, with progressive loss of quality of life. It has been reported that about 20 % of the entire human population undergoes a form of allergy. The prevalence of allergic conjunctivitis (AC) varies around the world, usually ranging from 15 to 40 %. In Japan, the prevalence of allergic diseases is the conjunctiva is estimated to be as high as 15% -20% of the population is on the rise. Objective: the present objective was to carry out a narrative and systematic review of the major clinical considerations of allergic conjunctivitis, as well as the main treatments, immunological aspects, and allergic conjunctivitis classification. Methods: The systematic review rules of the PRISMA Platform were followed. The research was carried out from May to June 2022 in Scopus, PubMed, Science Direct, Scielo, and Google Scholar databases. Scientific articles from the last 20 years were selected. The quality of the studies was based on the GRADE instrument. The risk of bias was analyzed according to the Cochrane instrument. Results: A total of 512 articles were found, and 35 articles were included in the systematic review. Allergic conjunctivitis (AC) is an inflammation of the conjunctiva secondary to an immune response to foreign antigens, usually called allergens. This inflammation can be mediated or non-IgE and atopy could play a significant role in the outcome. These forms include seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis. Giant papillary conjunctivitis and contact or induced by dermatoconjunctivitis drugs are considered to be allergic conjunctivitis subtypes. Conclusion: It was concluded that allergic conjunctivitis is a frequent comorbid with many undiagnosed patients. Then, an additional specific questioning and a therapeutic challenge in suspected patients may help identify patients who may benefit from treatment of Allergic conjunctivitis.

Introduction: Every year about 1 to 2 million people become blind and the number of blind people is predicted to reach 90 million in 2020. A cataract is the biggest cause of blindness in the world, except in developed countries. It accounts for 47.8% of the world's cases of blindness. A cataract is a name given to any opacity of the lens, which does not necessarily affect vision, with phacoemulsification being the main choice of treatment, which consists of a posterior aspiration of the emulsified material. Objective: The objective of this study was to evaluate, through a systematic review, the visual acuity, with less recourse to correction, in patients undergoing phacoemulsification with bilateral implants of hydrophobic lenses. Methods: The systematic review rules of the PRISMA Platform were followed. The literature search was carried out from July to August 2022 in Scopus, PubMed, Science Direct, Scielo, and Google Scholar databases. Scientific articles from the last 3 years were selected. The quality of the studies was based on the GRADE instrument. The risk of bias was analyzed according to the Cochrane instrument. Results and Conclusion: A total of 23 articles were included in this study, with 6 articles being from the main current clinical studies on the use of intraocular lenses. Both PCO value and Nd: YAG capsulotomy rates were higher in the hydrophobic acrylic IOL group than in the long-term use silicone (intraocular lens) IOL group (more than 6 years) after implantation. This study indicates excellent postoperative visual acuity and refractive results in the eyes following implantation of the EyeCee® One. This is accompanied by a very little risk of intraoperative and postoperative complications. Furthermore, the Aktis SP IOL is a safe, effective, and stable lens that can be inserted through a 2.2 mm incision with satisfactory visual and refractive results, even in the late postoperative period. Therefore, by analyzing the histopathological composition of PCO using LECs, more information can be gained about the characteristics of IOLs that are important for biocompatibility. Finally, patients implanted with trifocal IOLs showed a significant improvement in visual acuity at different distances, providing broad absolute and relative depth of field values, with good patient satisfaction rates.